Discovery of Small Molecules that Block Supt4h1-Supt5h Dimerization for Potential C9FTD/ALS Therapeutics

发现阻止 Supt4h1-Supt5h 二聚化的小分子,用于潜在的 C9FTD/ALS 治疗

基本信息

项目摘要

PROJECT SUMMARY C9FTD/ALS is a rapidly progressive and debilitating neurological disease caused by expansion of a simple tandem repeat sequence in the gene C9ORF72. C9FTD/ALS is the number one inherited cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). There are no effective treatments for C9FTD/ALS, nor the other neurological repeat expansion disorders In C9FTD/ALS and most other repeat expansion disorders, of which over two dozen exist, the repeat expansion is transcribed into expanded tandem repeat-containing RNA, or xtrRNA, which mediates the molecular mechanisms of disease. Although the molecular chain of events that lead to C9FTD/ALS pathology are still unclear, it is widely accepted that reducing or blocking production of the xtrRNA will lead to effective therapeutic treatments that can halt disease progression. The key will lie in identifying treatments that can selectively inhibit transcription of large repeat expansions without affecting normal gene expression. A protein called Supt4h1 (Spt4 in yeast) acts as a processivity factor to the core RNA polymerase II enzyme to improve transcription across repetitive, structurally complex, or large regions of the genome. Previous studies have demonstrated that Supt4h1 is largely dispensable in yeast and its knock-down in C9FTD/ALS model organisms and patient-derived cells significantly mitigates disease pathology. Supt4h1 interacts with RNA polymerase II through dimerization with Sup5h, a core transcription factor. A crystal structure of this dimer reveals precise molecular contacts. Thus, we will develop an Supt4h1- Supt5h dimerization assay that can rapidly report dimerization status and is amenable to high throughput drug screening. The assay is colorimetric and quick, making high throughput chemical library screening accessible and cost-effective. We will search for small molecules that inhibit dimerization. After counter- screening and titration of the best inhibitors, we will further characterize the ability of top molecules to block C9ORF72 xtrRNA transcription and downstream molecular markers of disease pathology in patient- derived cells. This project will potentially deliver lead small molecules for further development as drug candidates for C9FTD/ALS. This project may also help fill an urgent gap in therapeutics for a number of diseases comprising an entire class of neurological disorders. The Supt4h1-Supt5h dimerization assay developed here will be useful for screening other libraries of small molecules or active biologics.
项目总结 C9FTD/ALS是一种快速进展和衰弱的神经系统疾病,由 基因C9ORF72中的简单串联重复序列。C9FTD/ALS是遗传致病的头号原因 额颞性痴呆(FTD)和肌萎缩侧索硬化症(ALS)。目前还没有有效的治疗方法 对于c9FTD/ALS,以及其他神经重复扩张性疾病 在c9FTD/ALS和大多数其他重复扩张性疾病中,重复 扩展被转录为扩展的串联重复序列RNA,或xtrRNA,它介导 疾病的分子机制。尽管导致C9FTD/ALS的分子链 病理仍不清楚,人们普遍认为减少或阻止xtrRNA的产生将 导致有效的治疗方法,可以阻止疾病的进展。关键在于找出 选择性抑制大重复扩增转录而不影响正常的治疗 基因表达。 一种名为Supt4h1的蛋白质(酵母中的Spt4)作为核心RNA聚合酶II的加工因子 在重复的、结构复杂的或大范围的基因组区域中提高转录的酶。 先前的研究表明,Supt4h1在酵母中基本上是不必要的,它在酵母中的敲除 C9FTD/ALS模型生物和患者来源的细胞显著减轻疾病病理。 Supt4h1通过与核心转录因子Sup5h的二聚化作用与RNA聚合酶II相互作用。 这种二聚体的晶体结构显示了精确的分子接触。因此,我们将开发一款Supt4h1- Supt5h二聚检测,可快速报告二聚状态,并适用于高通量 药物筛查。该方法比色快速,可进行高通量的化学文库筛选 交通便利,性价比高。我们将寻找抑制二聚化的小分子。在柜台后- 筛选和滴定最好的抑制剂,我们将进一步表征顶端分子的能力 阻断C9ORF72 xtrRNA转录和下游疾病病理分子标志物- 派生的细胞。 该项目将潜在地提供铅小分子作为候选药物的进一步开发 C9FTD/ALS。该项目还可能有助于填补一些疾病的治疗方面的紧迫空白。 包括一整类神经性疾病。建立了Supt4h1-Supt5h二聚化实验 这将有助于筛选其他小分子或活性生物制品的文库。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Keith Thomas Gagnon其他文献

Keith Thomas Gagnon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Keith Thomas Gagnon', 18)}}的其他基金

Toward synthetic chemically defined mRNA for human therapeutics
用于人类治疗的合成化学定义的 mRNA
  • 批准号:
    10649299
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
  • 批准号:
    10864412
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
  • 批准号:
    10462348
  • 财政年份:
    2022
  • 资助金额:
    $ 8.79万
  • 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
  • 批准号:
    10615203
  • 财政年份:
    2022
  • 资助金额:
    $ 8.79万
  • 项目类别:
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
表观转录组学与持续残留 HIV 感染的分子疾病机制和核酸治疗的耦合
  • 批准号:
    10907304
  • 财政年份:
    2022
  • 资助金额:
    $ 8.79万
  • 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
  • 批准号:
    10079496
  • 财政年份:
    2020
  • 资助金额:
    $ 8.79万
  • 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
  • 批准号:
    10551318
  • 财政年份:
    2020
  • 资助金额:
    $ 8.79万
  • 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
  • 批准号:
    10322116
  • 财政年份:
    2020
  • 资助金额:
    $ 8.79万
  • 项目类别:
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases
用抗原 RNA 激活基因表达来治疗遗传性疾病
  • 批准号:
    8037089
  • 财政年份:
    2009
  • 资助金额:
    $ 8.79万
  • 项目类别:
Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases
用抗原 RNA 激活基因表达来治疗遗传性疾病
  • 批准号:
    8197067
  • 财政年份:
    2009
  • 资助金额:
    $ 8.79万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 8.79万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了